UY27293A1 - USE OF INDIRRUBINE SELECTIVE DERIVATIVES AS VEGR-R INHIBITORS - Google Patents

USE OF INDIRRUBINE SELECTIVE DERIVATIVES AS VEGR-R INHIBITORS

Info

Publication number
UY27293A1
UY27293A1 UY27293A UY27293A UY27293A1 UY 27293 A1 UY27293 A1 UY 27293A1 UY 27293 A UY27293 A UY 27293A UY 27293 A UY27293 A UY 27293A UY 27293 A1 UY27293 A1 UY 27293A1
Authority
UY
Uruguay
Prior art keywords
diseases
inhibitors
indirrubine
vegr
selective
Prior art date
Application number
UY27293A
Other languages
Spanish (es)
Inventor
Rolf Jautelat
Olaf Prien
Gerhard Siemeister
Karl Heinz Thierauch
Gerhard Eisenbrand
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27293A1 publication Critical patent/UY27293A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Uso de derivados selectivos de indirrubina como inhibidores de VRGR-R para preparar un medicamento para enfermedades tales como cánceres, tumores sólidos, leucemias, enfermedades autoinmunes, como psoriasis, alopecia y esclerosis múltiple, alopecia inducida por quimioterapéuticos y mucositosis, enfermedades cardiovasculares, enfermedades infecciosas, enfermedades nefrológicas, enfermedades neurodegenerativas crónicas, enfermedades neurodegenerativas agudas, infecciones virales como por ejemplo infecciones por citomegalovirus, herpes, hepatitis B o C, y enfermedades provocadas por HIV. Los compuestos de la invención también son útiles como inhibidores de VEGFR-3 en casos de linfangiogénesis.Use of selective indirubin derivatives as VRGR-R inhibitors to prepare a medicine for diseases such as cancers, solid tumors, leukemia, autoimmune diseases, such as psoriasis, alopecia and multiple sclerosis, chemotherapeutic and mucositosis-induced alopecia, cardiovascular diseases, infectious diseases , nephrological diseases, chronic neurodegenerative diseases, acute neurodegenerative diseases, viral infections such as cytomegalovirus infections, herpes, hepatitis B or C, and diseases caused by HIV. The compounds of the invention are also useful as inhibitors of VEGFR-3 in cases of lymphangiogenesis.

UY27293A 2001-05-17 2002-05-16 USE OF INDIRRUBINE SELECTIVE DERIVATIVES AS VEGR-R INHIBITORS UY27293A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10125763A DE10125763A1 (en) 2001-05-17 2001-05-17 New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections

Publications (1)

Publication Number Publication Date
UY27293A1 true UY27293A1 (en) 2003-02-28

Family

ID=7686282

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27293A UY27293A1 (en) 2001-05-17 2002-05-16 USE OF INDIRRUBINE SELECTIVE DERIVATIVES AS VEGR-R INHIBITORS

Country Status (3)

Country Link
DE (1) DE10125763A1 (en)
UY (1) UY27293A1 (en)
WO (1) WO2002092079A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP4037887B2 (en) * 2003-01-15 2008-01-23 ロレアル Care or makeup composition comprising 2-alkylideneaminooxyacetamide, its use for stimulating hair and / or eyelash growth and / or delaying their loss
FR2849773B1 (en) * 2003-01-15 2006-07-14 Oreal CAPILLARY COMPOSITION CONTAINING 2-ALKYLIDENE AMINOOXY-ACETAMIDE, ITS USE FOR STIMULATING HAIR GROWTH AND / OR BRAKING THEIR FALL
AR059066A1 (en) 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
ATE547411T1 (en) 2006-12-04 2012-03-15 Jiangsu Simcere Pharmaceutical R & D Co Ltd 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDROINDOLINONE DERIVATIVES AND USES THEREOF
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
CN103333161B (en) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 The preparation of 1 '-oxo Indirubin and purposes
CN107517589A (en) 2015-01-08 2017-12-26 小利兰·斯坦福大学托管委员会 The factor and cell of the induction of bone, marrow and cartilage are provided

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194468T3 (en) * 1998-05-29 2003-11-16 Centre Nat Rech Scient USE OF INDIGOID BISINDOL DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR INHIBITING CYCLINE DEPENDENT KINASES.
US6664285B1 (en) * 1999-04-12 2003-12-16 Gerhard Eisenbrand Use of cell membrane penetrating indigoid bisindole derivatives
HUP0200724A3 (en) * 1999-04-12 2002-10-28 Eisenbrand Gerhard Indigoid bisindole derivatives and pharmaceurical compositions containing them
FR2801216A1 (en) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Use of indirubine derivatives to inhibit 3 beta-glycogen synthase kinase, for the treatment of diabetes, neurodegenerative disorders, manic-depressive disorders, cancers, or parasites
DE10053474A1 (en) * 2000-10-24 2002-05-02 Schering Ag Indirubin derivatives containing sulfur, their production and use
DE10061162A1 (en) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituted indirubin derivatives, their preparation and use

Also Published As

Publication number Publication date
WO2002092079A1 (en) 2002-11-21
DE10125763A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
UY27293A1 (en) USE OF INDIRRUBINE SELECTIVE DERIVATIVES AS VEGR-R INHIBITORS
DE69333109D1 (en) THERAPEUTIC NUCLEOSIDES
ATE254132T1 (en) ANTIVIRAL PYRIMIDINE NUCLEOSIDE DERIVATIVES
WO2005021568A3 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
EA200100954A1 (en) CAMPTOTECINE DERIVATIVES, possessing anti-tumor activity
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
UY26886A1 (en) POLYMORPHES OF AN EPOTILONE ANALOG
ATE269321T1 (en) MEDICINAL PRODUCTS FOR VIRAL DISEASES
DOP2000000109A (en) THIAZOLILAMIDE DERIVATIVES
UY26982A1 (en) INDIRUBINE DERIVATIVES CONTAINING SULFUR, ITS PREPARATION AND USE
ES2102081T3 (en) MULTI-POWERFUL PARAMUNITY INDUCTORS BASED ON COMBINATIONS OF POXVIRUS COMPONENTS, METHODS FOR PREPARING THEM, AND THEIR USE AS DRUGS.
EP2289515A3 (en) Combinations comprising a diaryl urea and an interferon
IT8819807A0 (en) METHOD FOR THE CONSTRUCTION OF LARGE SPAN TUNNELS USING CELLULAR ARC.
TR200402534T4 (en) Oxazinoquinolones useful in the treatment of viral infections.
ATE287887T1 (en) COMPOUNDS THAT INHIBIT THE RELEASE OF CYTOKINES
FI882385A0 (en) PHOSPHORUS HMG-COA REDUCTIN INHIBITOR, FOERFARANDE FOER FRAMSTAELLNING DAERAV OCH NYA MELLANPRODUKTER.
DK315889A (en) ANTIVIRAL COMBINATIONS, RELATIONSHIPS USED HEREIN, AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMBINATIONS.
FI932997A0 (en) ANTIVIRAL FOERENINGAR
RU93055352A (en) METHOD FOR PRODUCING 5-SUBSTITUTED PYRROLO / 2,3-D / PYRIMIDINES
SE0300034L (en) Use of strains of Parapoxvirus ovis for the preparation of antiviral and anti-cancer drugs
FI885811A (en) THERE ARE AMMONIUM FOILENINGAR, DERAS FRAMSTAELLNING OCH ANVAENDNING.
ECSP034532A (en) DERIVATIVES OF 1-AMINOBUTAN-3-OL REPLACED
MX9305093A (en) NEW DERIVATIVESINDANO-2 MERCAPTOACETILAMINA TRICICLICOS 2-SUBSTITUTED, USEFUL AS ENCEPHALINASE INHIBITORS.
FI950229A (en) Tetracyclic compounds, processes and intermediates for their preparation and their use as antitumor agents
IT8821877A0 (en) CATALYST COMPONENT FOR THE PRODUCTION OF VERY HIGH MOLECULAR WEIGHT POLYOLEFINS.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141216